# Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer

> **NCT01535157** · PHASE1,PHASE2 · TERMINATED · sponsor: **South Plains Oncology Consortium** · enrollment: 12 (actual)

## Conditions studied

- Ovarian Cancer
- Cancer of Ovary
- Cancer of the Ovary
- Ovary Neoplasms
- Primary Peritoneal Carcinoma

## Interventions

- **DRUG:** Fenretinide/LXS + Ketoconazole

## Key facts

- **NCT ID:** NCT01535157
- **Lead sponsor:** South Plains Oncology Consortium
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-02
- **Primary completion:** 2017-06
- **Final completion:** 2017-06
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** drug combination not providing any efficacy. Will use this data in opening new trial
- **Last updated:** 2020-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01535157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01535157, "Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01535157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*